透析患者新发糖尿病风险:台湾登记数据分析
结果显示腹透患者新发糖尿病风险高于血透患者,而艾考糊精使用与腹透患者新发糖尿病风险降低相关。
要点
- 腹透患者新发糖尿病风险高于血透患者,倾向评分匹配后校正HR为1.61。
- 腹透患者中使用艾考糊精者新发糖尿病风险低于非使用者,校正HR为0.66。
- 建议腹透患者使用艾考糊精以降低新发糖尿病风险。
核心结论
- 腹透患者新发糖尿病风险高于血透患者,艾考糊精可降低腹透患者新发糖尿病风险。
主要发现
- 未匹配队列中,腹透患者新发糖尿病发生率9.16/1000人年,血透患者8.18/1000人年,腹透校正HR为1.51(95%CI 1.30-1.75)。
- 倾向评分匹配队列中,腹透和血透新发糖尿病发生率分别为9.43和5.90/1000人年,腹透校正HR为1.61(95%CI 1.32-1.97)。
- 腹透患者中,艾考糊精使用者新发糖尿病发生率6.22/1000人年,非使用者12.1/1000人年,使用者校正HR为0.66(95%CI 0.50-0.88)。
关键数值与推荐
- 腹透患者新发糖尿病风险较血透患者显著升高,未匹配校正HR 1.51(95%CI 1.30-1.75),匹配后校正HR 1.61(95%CI 1.32-1.97)。
- 腹透患者使用艾考糊精者新发糖尿病风险显著低于非使用者,校正HR 0.66(95%CI 0.50-0.88)。
临床怎么用
- 对腹透患者应关注新发糖尿病风险,可考虑使用艾考糊精以降低该风险。
局限性
- 本研究为基于登记数据库的回顾性观察性研究,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study compared the risk of developing new-onset diabetes between hemodialysis (HD) and peritoneal dialysis (PD) patients. We further investigated the effectiveness of icodextrin in reducing the risk of new-onset diabetes in PD patients. METHODS: From the Taiwan health insurance database, 36 879 incident HD patients and 6382 incident PD patients from 2000 to 2010 were identified as study cohorts. We further selected an additional HD cohort matched by propensity scores (PSs) of PD patients. Incidence rates and hazard ratios (HRs) of new-onset diabetes were assessed among cohorts and between icodextrin users and nonusers by the end of 2011. RESULTS: For the unmatched cohorts, the incidence of new-onset diabetes was higher in PD patients than in HD patients (9.16 versus 8.18 per 1000 person-years), with an adjusted HR of 1.51 (95% CI 1.30-1.75) for PD patients. For the PS-matched cohorts, the corresponding incidence rates were 9.43 and 5.90 per 1000 person-years, respectively, with an adjusted HR of 1.61 (95% CI 1.32-1.97). Among PD patients, the incidence was lower in icodextrin users than in nonusers (6.22 versus 12.1 per 1000 person-years), with an adjusted HR of 0.66 (95% CI 0.50-0.88) for users. CONCLUSIONS: Our study suggests that PD patients are at a higher risk of developing new-onset diabetes than HD patients. Icodextrin is recommended for PD patients to reduce the risk of new-onset diabetes.
引用
- Wang IK, Lin CL, Chen HC, et al. Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: analysis from registry data of Taiwan. Nephrol Dial Transplant. 2018. PMID: 28992134. doi:10.1093/ndt/gfx250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。